8-K: Paysign Reports Strong 2023 Results with Revenue Up 24% and Net Income Surging

Paysign, Inc. announced a robust financial performance for 2023, highlighted by a 24% increase in revenue and a significant rise in net income.

Summary

• Paysign reported full-year 2023 total revenues of $47.3 million, a 24% increase compared to 2022.
• Net income for the full year was $6.5 million, or $0.12 per diluted share, a substantial improvement from $1.0 million, or $0.02 per diluted share, in the previous year.
• Adjusted EBITDA for 2023 reached $6.7 million, up 21% from $5.5 million in 2022.
• The company's plasma revenue increased by 21%, driven by a 20-center increase in plasma locations, ending the year with 464 centers.
• Pharma patient affordability revenue saw a remarkable 172% increase, with 24 new programs launched, bringing the total to 43 active programs.
• Paysign exited the year with $17.0 million in unrestricted cash and no debt, while also repurchasing 394,558 shares for $1.1 million.
• Fourth quarter 2023 total revenues were $13.7 million, a 29% increase year-over-year, with net income of $5.6 million, or $0.10 per diluted share.
• Adjusted EBITDA for the fourth quarter was $2.5 million, a 43% increase from the same period last year.
• The average revenue per plasma center per month increased by 14% to $8,297 in the fourth quarter of 2023.

Sentiment

Score: 9

Explanation: The document conveys a very positive sentiment due to the strong financial results, significant growth in key areas, and optimistic future outlook. The company's management expresses confidence in their strategic direction and market position.

Positives

• Paysign achieved strong revenue growth of 24% for the full year 2023.
• The company's net income saw a substantial increase, reaching $6.5 million for the full year.
• Adjusted EBITDA grew by 21% for the full year, indicating improved operational performance.
• The plasma business experienced a healthy 21% revenue increase.
• The pharma patient affordability segment showed exceptional growth with a 172% revenue increase.
• Paysign successfully added 20 new plasma donation centers and 24 new patient affordability programs.
• The company ended the year with a strong cash position of $17.0 million and no debt.
• Paysign repurchased shares, demonstrating confidence in the company's value.
• The fourth quarter also showed strong growth with a 29% increase in revenue and a 43% increase in Adjusted EBITDA.
• Average revenue per plasma center per month increased by 14% in the fourth quarter.

Negatives

• The cost of revenues increased by 35% for the full year, impacting gross profit margins.
• Gross profit margin decreased to 51.1% for the full year, compared to 55.1% in the prior year.
• Selling, general, and administrative expenses increased by 15% for the full year due to increased hiring and compensation costs.
• Depreciation and amortization expenses increased by 38% for the full year due to software development and equipment purchases.

Risks

• The company's future growth rate may not be sustainable.
• Economic downturns could reduce the customer base and demand for Paysign's products and services.
• Operating in a highly regulated environment poses compliance risks.
• Data security breaches could lead to liability and litigation.
• Changes in laws, regulations, or industry standards could negatively impact the business.

Future Outlook

Paysign anticipates continued growth across all business units in 2024, with the patient affordability business expected to experience triple-digit year-over-year growth. Full-year 2024 revenue is projected to be between $54.5 million and $56.7 million, with adjusted EBITDA between $8.0 million and $9.0 million. First quarter 2024 revenue is expected to be between $12.0 million and $13.0 million, with adjusted EBITDA between $1.2 million and $1.5 million.

Management Comments

• Mark Newcomer, President & CEO of Paysign, stated that they are exceptionally pleased with their financial performance in 2023, marking a year of continued strong growth.
• Mark Newcomer noted that the patient affordability business has emerged as a significant growth driver, experiencing an impressive 172% revenue growth.
• Jeff Baker, Paysign CFO, mentioned that the decision five years ago to invest in the pharma patient affordability business is paying off and expects that momentum to continue throughout 2024.

Industry Context

Paysign's strong performance, particularly in the patient affordability sector, highlights the growing importance of specialized payment solutions within the healthcare industry. The company is leveraging disruptions in the pharmaceutical payments space to its advantage, indicating a strategic approach to market opportunities.

Comparison to Industry Standards

• While specific competitor data isn't provided in the document, Paysign's 24% revenue growth and 21% Adjusted EBITDA growth for the full year 2023 are strong indicators of performance in the financial technology sector.
• The 172% growth in pharma patient affordability revenue is particularly noteworthy, suggesting a leading position in this niche market.
• The company's expansion in plasma centers and patient affordability programs demonstrates a proactive approach to market penetration.
• The increase in average revenue per plasma center per month by 14% indicates improved efficiency and profitability within the plasma business.

Stakeholder Impact

• Shareholders will benefit from the strong financial performance and positive future outlook.
• Employees may see increased opportunities due to the company's growth.
• Customers will benefit from the company's continued investment in technology and services.
• Suppliers may see increased business opportunities due to the company's growth.

Next Steps

• Paysign will continue to focus on growing its plasma and patient affordability businesses.
• The company plans to add new plasma centers and patient affordability programs throughout 2024.
• Paysign will continue to invest in people and technology to support its growth.
• The company will hold a conference call to discuss the financial results.

Key Dates

Keywords

prepaid cards, patient affordability, digital banking, payment processing, plasma, pharmaceutical, revenue, EBITDA, net income, financial results